HeartBeam, a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection has announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended for detection of myocardial infarction (MI) and complex cardiac arrhythmias has been granted by the United States Patent and Trademark Office. The innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting, the company said in a press release.
According to HeartBeam, currently available wearables are not capable of providing a 12-lead ECG for myocardial infarction detection, complex arrhythmia monitoring or other cardiac disorders.
“The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection,” said HeartBeam CEO and founder Branislav Vajdic.
While HeartBeam is presently focused on the development, clinical and regulatory activities for the HeartBeam AIMI and AIMIGo systems, the company is committed to continue advancing its 12-lead 3D vector ECG technology as demonstrated in recently issued and allowed patents.